Prime Medicine, Inc.
Income Statement
| Line Item | Aug 2024 | Jun 2024 | May 2024 | Mar 2024 | Feb 2024 | Dec 2023 | Oct 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | $591.0K | — | — | — | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $43.1M | — | $37.8M | — | — | — | $41.0M |
| SG&A Expense | — | $12.6M | — | $11.2M | — | — | — | $10.5M |
| Operating Income | — | $-55.7M | — | $-48.3M | — | — | — | $-51.5M |
| Operating Margin | — | — | — | -8,179.5% | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $-134.0K | — | $134.0K | — | — | — | $-108.0K |
| Net Income | — | $-55.3M | — | $-45.8M | — | — | — | $-50.7M |
| Net Margin | — | — | — | -7,743.0% | — | — | — | — |
| EPS (Basic) | — | $-0.46 | — | $-0.44 | — | — | — | $-0.18 |
| EPS (Diluted) | — | $-0.46 | — | $-0.44 | — | — | — | $-0.18 |
| Shares Outstanding (Basic) | 120.0M | 119.2M | 120.0M | 104.5M | 119.9M | 97.4M | 292.0M | 275.5M |
| Shares Outstanding (Diluted) | 120.0M | 119.2M | 120.0M | 104.5M | 119.9M | 97.4M | 292.0M | 275.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |
The intelligent investor is a realist who sells to optimists and buys from pessimists.